# Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)

> **NCT00294164** · PHASE2,PHASE3 · COMPLETED · sponsor: **EMD Serono** · enrollment: 245 (actual)

## Conditions studied

- Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
- Human Immunodeficiency Virus Infections

## Interventions

- **DRUG:** Serostim®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00294164
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** 2002-05
- **Final completion:** 2002-05
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2014-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00294164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00294164, "Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00294164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*